ArticleInternational journal of clinical oncology2026
Treatment strategies and outcomes in patients with synchronous multiple primary malignancies involving lung cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSynchronous multiple primary malignancies (sMPMs) involving lung cancer present complex clinical challenges requiring individualized treatment strategies. While surgical outcomes have been reported, data on long-term outcomes, including the development of new additional primary malignancies after surgery, remain limited.
methodsWe retrospectively analyzed 85 patients with sMPMs involving lung cancer selected from 2820 patients who underwent pulmonary resection between 2008 and 2020. Surgical strategies, treatment sequence, perioperative outcomes, and long-term survival were evaluated. The incidence of new additional primary malignancies was assessed using person-time and competing risk analysis.
resultsAmong the 85 patients, lung cancer was treated first in 30, the other malignancy first in 41, and simultaneous surgery was performed in 14. Lobectomy was the most common procedure (73%). Postoperative complications occurred in 22% of patients. The 5-year recurrence-free survival and overall survival rates were 63 and 69%, respectively. During 485.3 person-years of follow-up, 11 patients developed new additional primary malignancies, corresponding to an incidence rate of 22.7 per 1000 person-years. In competing risk analysis, the cumulative incidence was 6.0% at 5 years and 20.3% at 10 years after lung cancer surgery.
conclusionSurgical treatment for lung cancer is feasible in selected patients with sMPMs. The occurrence of new additional primary malignancies should be recognized as a clinically relevant aspect of postoperative management.
Indexed as
Identifiers
42298054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.